Royalty Pharma plc revenue by year
Over the 8 fiscal years shown, revenue went from $1.79B (year ended Dec 31, 2018) to $2.38B (year ended Dec 31, 2025), a compound annual growth rate of 4.1%. The fastest growth was +17.0% in the year ended Dec 31, 2020; the weakest year was −3.9% (year ended Dec 31, 2024).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $2.38B | +5.1% | Revenues | 10-K filed Feb 11, 2026 |
| Dec 31, 2024 | $2.26B | −3.9% | Revenues | 10-K filed Feb 11, 2026 |
| Dec 31, 2023 | $2.35B | +5.2% | Revenues | 10-K filed Feb 11, 2026 |
| Dec 31, 2022 | $2.24B | −2.3% | Revenues | 10-K filed Feb 12, 2025 |
| Dec 31, 2021 | $2.29B | +7.9% | Revenues | 10-K filed Feb 15, 2024 |
| Dec 31, 2020 | $2.12B | +17.0% | Revenues | 10-K filed Feb 15, 2023 |
| Dec 31, 2019 | $1.81B | +1.1% | Revenues | 10-K filed Feb 15, 2022 |
| Dec 31, 2018 | $1.79B | — | Revenues | 10-K filed Feb 24, 2021 |
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Jun 30, 2026 | $674.14M | +16.5% | 10-Q filed Aug 5, 2026 |
| 3 months ended Mar 31, 2026 | $630.58M | +11.0% | 10-Q filed May 6, 2026 |
| 3 months ended Sep 30, 2025 | $609.29M | +7.9% | 10-Q filed Nov 5, 2025 |
| 3 months ended Jun 30, 2025 | $578.66M | +7.7% | 10-Q filed Aug 5, 2026 |
| 3 months ended Mar 31, 2025 | $568.25M | +0.0% | 10-Q filed May 6, 2026 |
| 3 months ended Sep 30, 2024 | $564.69M | +5.3% | 10-Q filed Nov 5, 2025 |
| 3 months ended Jun 30, 2024 | $537.27M | −0.2% | 10-Q filed Aug 6, 2025 |
| 3 months ended Mar 31, 2024 | $567.98M | −17.0% | 10-Q filed May 8, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 1802768 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.